Drug-induced granulomatosis is dupilumab the new kid on the block? - Archive ouverte HAL Access content directly
Journal Articles Journal of the European Academy of Dermatology and Venereology Year : 2020

Drug-induced granulomatosis is dupilumab the new kid on the block?

(1) , (1) , (1, 2) , (3) , (3) , (1) , (2, 4) , (1) , (1, 2) , (1) , (1) , (1, 2) , (1, 2)
1
2
3
4

Abstract

Dupilumab is an IgG4 antibody directed toward IL-4 and IL-13, two major effectors of the Th2 immunity response. It was originally developed for severe and/or refractory atopic dermatitis, nevertheless its use has secondarily been broadened to severe asthma . We report herein the case a 28-year-old, non-smoker male who presented to the emergency department with confusion, headaches, emesis and photophobia. His medical history included only a severe atopic dermatitis leading to dupilumab initation 4 months earlier. Physical examination revealed a meningoencephalitis syndrome, and a bilateral parotidomegaly.
Fichier principal
Vignette du fichier
Belhomme et al-Drug-induced granulomatosis.pdf (631.9 Ko) Télécharger le fichier
Origin : Files produced by the author(s)
Loading...

Dates and versions

hal-02470892 , version 1 (26-02-2020)

Identifiers

Cite

N Belhomme, T Gaignon, S Jouneau, L Misery, C Abasq-Thomas, et al.. Drug-induced granulomatosis is dupilumab the new kid on the block?. Journal of the European Academy of Dermatology and Venereology, 2020, 34 (7), ⟨10.1111/jdv.16218⟩. ⟨hal-02470892⟩
138 View
598 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More